|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:Dun_&_Bradstreet_Corporate_Awards
Forbes Asia 'Best Under a Billion'
|
|
gptkbp:CEO
|
Glenn Saldanha
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focusArea
|
gptkb:diabetes
cardiology
infectious diseases
oncology
dermatology
respiratory
|
|
gptkbp:foundedBy
|
Gracias Saldanha
|
|
gptkbp:foundedYear
|
1977
|
|
gptkbp:hasResearchCenter
|
gptkb:India
gptkb:Switzerland
gptkb:USA
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Glenmark Pharmaceuticals
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
INE935A01035
|
|
gptkbp:manufacturingFacilities
|
gptkb:Argentina
gptkb:Brazil
gptkb:Czech_Republic
gptkb:India
gptkb:Mexico
gptkb:Poland
gptkb:Russia
gptkb:USA
gptkb:Venezuela
|
|
gptkbp:market
|
global
|
|
gptkbp:numberOfEmployees
|
over 13,000
|
|
gptkbp:parentCompany
|
Glenmark Group
|
|
gptkbp:products
|
generic drugs
active pharmaceutical ingredients
branded formulations
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:revenue
|
over $1 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
GLENMARK
|
|
gptkbp:subsidiary
|
Glenmark Life Sciences
|
|
gptkbp:website
|
https://www.glenmarkpharma.com/
|
|
gptkbp:bfsParent
|
gptkb:Cipla_Limited
gptkb:Zola_Maal
|
|
gptkbp:bfsLayer
|
7
|